Novo Nordisk China R&D Day 2024: Envisioning a Future Free from Serious Chronic Diseases – Focusing on Diabetes and Obesity
Invitation Letter
2024 marks the 30th anniversary of Novo Nordisk China. How has Novo Nordisk continued to overcome challenges during the R&D phase, particularly in the fields of diabetes and obesity? Standing at a new starting point and looking to the future, what cutting-edge technologies and therapies is Novo Nordisk focusing on? How does Novo Nordisk plan to accelerate the delivery of innovative treatment solutions to patients in China?
Scheduled to be held in Beijing on August 30, with the theme of“Envisioning a Future Free from Serious Chronic Diseases—Focusing on Diabetes and Obesity” Novo Nordisk China R&D DayDuring the event, we will invite distinguished guests to share their insights on these topics.
We sincerely invite industry professionals with an interest to attend in person for exchange and interaction!
Limited Seats Available
We recommend that you scan the QR code to register as soon as possible.
Location:Hyatt Regency Beijing Wangjing
Time:August 30, 9:00 - 19:00
Language:English
This event will showcase several highlights for the audience:
Highlight 1 (Morning Session)
Keynote Speakers
Not only will Novo Nordisk’s global R&D leadership and China executives be in full attendance, but key opinion leaders in the diabetes and obesity fields will also be invited to attend.It features Novo Nordisk’s global R&D strategy and development journey, along with cutting-edge academic insights.
Senior Vice President, Novo Nordisk GlobalAlso President, Greater China
Novo Nordisk Global Drug DiscoverySenior Vice President
Novo Nordisk Global R&D TechnologySenior Vice President
Peking University People's Hospital
Highlight 2 (Afternoon Session)
“Star Start” Innovation Competition Roadshow and Awards Ceremony
The “Star Starting Point” Innovation Competition, jointly launched in 2022 by Novo Nordisk China R&D Center and ATLATL Innovation Center, focuses on innovative translational projects in the fields of biopharmaceuticals and biotechnology. Each year, a global expert review committee composed of representatives from both organizing parties selects two winning teams.
Recruitment for the 2024 “Star Start” Innovation Competition was launched in April this year. On the day of the R&D Day event, the five projects shortlisted in the first round will conduct public roadshows and engage with the judging committee and on-site audience. The final results of the innovation competition will also be announced on-site, followed by the award ceremony.
Highlight 3 (Afternoon Session)
Close Encounter with the GLP-1 R&D Leader
Lotte Bjerre Knudsen
Chief Scientific Advisor, Novo Nordisk
Lotte has worked at Novo Nordisk for over 30 years, dedicating herself to GLP-1 research. She has led the design, invention, and mechanistic studies of GLP-1-based therapeutics and has published numerous papers on the effects of GLP-1 drugs on diabetes, cardiovascular disease, and obesity. In recent years, her publications have focused on understanding the effects of GLP-1 on the brain.
Highlight 4 (Afternoon Session)
Open Discussion Session
In addition to the packed agenda, the event also features a cocktail reception, offering attendees a rare opportunity for face-to-face interactions with Novo Nordisk’s global executives and industry peers.
Limited Event Seating
We recommend that you scan the QR code to register as soon as possible.
If your registration is successful, you will receive a confirmation email within two weeks.Stay tuned!